Literature DB >> 27299180

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Audrey Mansuet-Lupo1,2,3,4, Marco Alifano3,5, Nicolas Pécuchet6, Jérôme Biton1,2,3, Etienne Becht1,2,3, Jeremy Goc1,2,3, Claire Germain1,2,3, Hanane Ouakrim1,2,3, Jean-François Régnard3,5, Isabelle Cremer1,2,3, Pierre Laurent-Puig3,7,6, Marie-Caroline Dieu-Nosjean1,2,3, Hélène Blons3,7,6, Diane Damotte1,2,3,4.   

Abstract

RATIONALE: Tumor-infiltrating immune cells affect lung cancer outcome. However, the factors that influence the composition and function of the tumor immune environment remain poorly defined and need investigation, particularly in the era of immunotherapy.
OBJECTIVES: To determine whether the tumoral immune environment is related to lung adenocarcinoma mutations.
METHODS: This retrospective cohort included 316 consecutive patients with lung adenocarcinoma (225 men; 258 smokers) studied from 2001 to 2005 in a single center. We investigated the association of densities of intratumoral mature dendritic cells (mDCs), CD8+ T cells, neutrophils, and macrophages with clinical and pathological variables and tumor cell mutation profiles obtained by next-generation sequencing.
MEASUREMENTS AND MAIN RESULTS: In 282 tumors, we found 460 mutations, mainly in TP53 (59%), KRAS (40%), STK11 (24%), and EGFR (14%). Intratumoral CD8+ T-cell density was high in smokers (P = 0.02) and TP53-mutated tumors (P = 0.02) and low in BRAF-mutated tumors (P = 0.005). Intratumoral mDC density was high with low pathological tumor stage (P = 0.01) and low with STK11 mutation (P = 0.004). Intratumoral neutrophil density was high and low with BRAF mutation (P = 0.04) and EGFR mutation (P = 0.02), respectively. Intratumoral macrophage density was low with EGFR mutation (P = 0.01). Intratumoral CD8+ T-cell and mDC densities remained strong independent markers of overall survival (P = 0.001 and P = 0.02, respectively).
CONCLUSIONS: Intratumoral immune cell densities (mDCs, CD8+ T cells, neutrophils, macrophages) were significantly associated with molecular alterations in adenocarcinoma underlying the interactions between cancer cells and their microenvironment.

Entities:  

Keywords:  CD8+ T cells; lung adenocarcinoma; mature dendritic cells; molecular alterations; prognostic factors

Mesh:

Year:  2016        PMID: 27299180     DOI: 10.1164/rccm.201510-2031OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  21 in total

1.  Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Authors:  Hélène Roussel; Eléonore De Guillebon; Lucie Biard; Marion Mandavit; Laure Gibault; Elisabeth Fabre; Martine Antoine; Paul Hofman; Michèle Beau-Faller; Hélène Blons; Claire Danel; Françoise Le Pimpec Barthes; Alain Gey; Clémence Granier; Marie Wislez; Pierre Laurent-Puig; Stéphane Oudard; Patrick Bruneval; Cécile Badoual; Jacques Cadranel; Eric Tartour
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

2.  Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Authors:  Maria I Toki; Nikita Mani; James W Smithy; Yuting Liu; Mehmet Altan; Brad Wasserman; Rasikh Tuktamyshov; Kurt Schalper; Konstantinos N Syrigos; David L Rimm
Journal:  J Thorac Oncol       Date:  2018-09-26       Impact factor: 15.609

3.  Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?

Authors:  Kenichi Suda
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.

Authors:  Yonina R Murciano-Goroff; Terry Pak; Sebastian Mondaca; Jessica R Flynn; Joseph Montecalvo; Natasha Rekhtman; Darragh Halpenny; Andrew J Plodkowski; Stephanie L Wu; Mark G Kris; Paul K Paik; Gregory J Riely; Helena A Yu; Charles M Rudin; Matthew D Hellmann; Josiah D Land; Larry W Buie; Glenn Heller; Piro Lito; Rona Yaeger; Alexander Drilon; Dazhi Liu; Bob T Li; Michael Offin
Journal:  Br J Cancer       Date:  2021-12-28       Impact factor: 9.075

Review 5.  Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.

Authors:  Giulia Mazzaschi; Alessandro Leonetti; Roberta Minari; Letizia Gnetti; Federico Quaini; Marcello Tiseo; Francesco Facchinetti
Journal:  Curr Treat Options Oncol       Date:  2021-09-15

6.  Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer.

Authors:  Marco Alifano
Journal:  Ann Transl Med       Date:  2020-06

Review 7.  Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.

Authors:  Yosuke Miura; Noriaki Sunaga
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

8.  CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining.

Authors:  Kentaro Inamura; Yasuyuki Shigematsu; Hironori Ninomiya; Yasuhiro Nakashima; Maki Kobayashi; Haruyuki Saito; Katsuhiro Takahashi; Etsuko Futaya; Sakae Okumura; Yuichi Ishikawa; Hiroaki Kanda
Journal:  Cancers (Basel)       Date:  2018-07-31       Impact factor: 6.639

9.  Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma.

Authors:  Yangyang Liu; Yue Hu; Feifei Gu; Jinyan Liang; Yulan Zeng; Xiaohua Hong; Kai Zhang; Li Liu
Journal:  Oncotarget       Date:  2017-06-28

Review 10.  Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.

Authors:  Charlotte Domblides; Juliette Rochefort; Clémence Riffard; Marylou Panouillot; Géraldine Lescaille; Jean-Luc Teillaud; Véronique Mateo; Marie-Caroline Dieu-Nosjean
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.